The current standard front-line treatment for small-cell NEPC involves either cytotoxic platinum-based regimens alone or in combination with anti-PD-L1 checkpoint inhibitors, regimens largely extrapolated from those used for small-cell lung cancer [6, 13, 14]. The gene discussed is CD274; the disease is small cell lung carcinoma.